Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Egalet plans NDA for oral morphine product

This article was originally published in Scrip

Executive Summary

Egalet said it plans to file a new drug application (NDA) by the end of 2015 for Egalet-001, an abuse-deterrent, extended-release, oral morphine product in development for the management of pain severe enough to require continuous opioid treatment. This comes after the US FDA provided feedback "supportive of Egalet's revised investigational plan designed to demonstrate bioequivalence (BE) of Egalet-001 to MS Contin," said the Wayne, PA-based firm. It also reported positive top-line results from a pivotal study (Study 067-EG-012) that demonstrated BE of Egalet-001 15mg and 30mg to MS Contin. Egalet is planning a pivotal 60 mg BE study which also will assess the effect of food on Egalet-001 by the end of this month. Egalet raised $50m in an IPO last year.

You may also be interested in...

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.

Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer

Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts